Aluminum Oxide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aluminum Oxide: No Repurposing Prediction Available
One-Sentence Summary
Aluminum Oxide (DrugBank ID: DB11342) is an inorganic compound with no registered original therapeutic indications in this evidence pack, and the TxGNN model generated no predicted new indications for this compound. The drug is not marketed in the US, with zero NDA licenses on record. Currently, no clinical trials or supporting publications are available to evaluate any repurposing direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available |
| Predicted New Indication | None — TxGNN generated no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no predictions, no supporting studies) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Not applicable — no predicted indications were generated by TxGNN for this compound.
Currently, detailed mechanism of action data is not available for Aluminum Oxide. Although the DrugBank record (DB11342) was successfully retrieved, no original therapeutic indications or mechanism-of-action data were returned. Without a valid prediction target, any mechanism-to-indication analysis would be speculative.
It is worth noting that Aluminum Oxide is most commonly encountered as a pharmaceutical excipient (e.g., coating agent, adsorbent) or industrial abrasive rather than a primary therapeutic agent. This classification may explain the absence of TxGNN predictions, as the model is optimized for compounds with established pharmacological activity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Aluminum Oxide has no NDA licenses or approved products recorded in the queried dataset.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN predictions were generated for Aluminum Oxide, the compound carries no US market authorization, and critical data including mechanism of action and safety profiles are entirely absent — making a repurposing evaluation impossible at this stage.
To proceed, the following is needed:
- Clarify drug role: Confirm whether DB11342 (Aluminum Oxide) is intended as a standalone therapeutic agent or is being evaluated solely as a pharmaceutical excipient; if the latter, repurposing evaluation is likely not applicable
- Obtain MOA data: Query the DrugBank API directly for pharmacological action, targets, and enzyme interactions for DB11342
- Download safety data: If any applicable formulation exists, retrieve and parse the package insert PDF for contraindications and warnings
- Re-run TxGNN pipeline: Verify whether the absence of predictions reflects expected model behavior (e.g., compound is out-of-scope) or a pipeline error upstream (e.g., failed DrugBank-to-KG node mapping)
- Check KG node presence: Confirm that DB11342 is present as a node in the TxGNN knowledge graph (
data/node.csv); if absent, the compound cannot be scored and must be excluded or manually addedDisclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.